Nu Skin (NUS) AI Stock Analysis

• Market Cap: $507.49M
• Dividend Yield: 2.31%
• Average Volume (3M): 451.77K
• Price to Earnings (P/E): 4.8
• Beta (1Y): 1.09
• Revenue Growth: -12.10%
• EPS Growth: N/A
• Country: US
• Employees: 3,100
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.34
• Shares Outstanding: 48,750,076
• 10 Day Avg. Volume: 466,464
• 30 Day Avg. Volume: 451,767
• PEG Ratio: <0.01
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.20
• P/FCF Ratio: 4.88
• Enterprise Value/Market Cap: 1.28
• Enterprise Value/Revenue: 0.42
• Enterprise Value/Gross Profit: 0.62
• Enterprise Value/Ebitda: 3.40
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.26
• Revenue Forecast (FY): $1.52B

• Rating: 61 Neutral
• Price Target: $10.50 ▲(0.86% Upside)

Nu Skin's overall stock score reflects a balance of positive valuation and strategic growth initiatives against the backdrop of declining revenue and cash flow. The company's strong performance in emerging markets and product innovation are promising, but operational challenges and market pressures remain significant risks.

Positive Factors

Emerging Market Growth

Strong growth in Latin America underscores Nu Skin's successful expansion strategy in emerging markets, providing a durable revenue stream.

Product Innovation

The launch of Prysm iO reflects Nu Skin's commitment to innovation, potentially driving long-term growth and market differentiation.

Improved Margins

Consistent margin improvement indicates effective cost management and product mix optimization, enhancing profitability sustainability.

Negative Factors

Declining Revenue

Declining revenue growth poses a challenge to Nu Skin's financial health, potentially impacting long-term business stability.

Free Cash Flow Decline

A decline in free cash flow generation limits Nu Skin's ability to invest in growth opportunities and maintain financial flexibility.

Challenges in North America

Ongoing difficulties in North America highlight regional vulnerabilities that could hinder overall company performance and growth.

Nu Skin Business Overview & Revenue Model

Company Description

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.

How the Company Makes Money

Nu Skin generates revenue primarily through the sale of its personal care and nutritional products. The company employs a direct selling model, where independent distributors earn commissions on their sales and the sales made by their recruited team members. This multi-level marketing structure allows Nu Skin to expand its market reach while incentivizing distributors to promote and sell products. Key revenue streams include skincare products, dietary supplements, and wellness devices. Additionally, Nu Skin invests in technological advancements and maintains partnerships with research institutions, enhancing its product offerings and brand credibility, which further contribute to its earnings.

Nu Skin Financial Statement Overview

Summary

Nu Skin's financial performance is mixed, with declining revenue and cash flow trends posing challenges. Despite improvements in profitability and leverage, operational inefficiencies need addressing to enhance financial health.

Income Statement

Nu Skin's income statement shows a declining trend in revenue with a negative growth rate of -4.05% in the TTM. The gross profit margin remains relatively strong at 67.20%, but the net profit margin has improved to 7.02% from negative figures in previous years. However, EBIT margin is negative, indicating operational challenges. Overall, while profitability metrics show some improvement, the declining revenue trend is a concern.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.36, indicating a manageable level of leverage. Return on equity has improved to 14.65% in the TTM, showing better utilization of equity. The equity ratio is stable, suggesting a balanced capital structure. While the company has reduced its debt, the overall asset base has slightly decreased, which could impact future growth.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by -8.99% in the TTM. The operating cash flow to net income ratio is 0.35, indicating moderate cash generation relative to net income. The free cash flow to net income ratio is 0.60, showing some efficiency in converting income to cash. Despite these metrics, the negative growth in free cash flow is a concern for future liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.56B	1.73B	1.97B	2.23B	2.70B	2.58B
Gross Profit	1.05B	1.18B	1.36B	1.59B	2.02B	1.92B
EBITDA	191.82M	-78.83M	202.98M	174.97M	368.48M	331.56M
Net Income	109.61M	-146.59M	8.60M	104.78M	147.27M	191.35M
Balance Sheet
Total Assets	1.42B	1.47B	1.81B	1.82B	1.91B	1.96B
Cash, Cash Equivalents and Short-Term Investments	253.00M	197.99M	267.82M	278.51M	354.81M	423.90M
Total Debt	291.43M	478.23M	607.33M	520.52M	503.79M	500.38M
Total Liabilities	624.61M	817.46M	984.50M	923.67M	993.71M	1.06B
Stockholders Equity	799.79M	651.46M	821.97M	897.30M	912.77M	894.27M
Cash Flow
Free Cash Flow	53.35M	70.16M	60.15M	49.01M	72.97M	315.32M
Operating Cash Flow	89.45M	111.74M	118.64M	108.06M	141.58M	379.14M
Investing Cash Flow	166.80M	-37.96M	-134.50M	-67.08M	-88.73M	-79.43M
Financing Cash Flow	-227.53M	-133.18M	10.73M	-99.50M	-104.70M	-245.17M

Nu Skin Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Positive. The current price of 10.41 is above the 20-day moving average (MA) of 10.03, below the 50-day MA of 10.82, and above the 200-day MA of 8.91, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 53.54 is Neutral, neither overbought nor oversold. The STOCH value of 92.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUS.

Nu Skin Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELF	67 Neutral	$4.49B	53.32	8.77%	―	13.80%	-25.02%
EPC	63 Neutral	$828.46M	33.41	1.62%	3.26%	-1.34%	-73.59%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
NUS	61 Neutral	$507.49M	4.78	14.55%	2.31%	-12.10%	―
COTY	47 Neutral	$2.89B	―	-9.96%	―	-5.68%	-358.36%
SKIN	47 Neutral	$175.02M	-4.90	-18.73%	―	-13.14%	57.98%
EL	46 Neutral	$33.77B	―	-20.73%	1.49%	-6.36%	-554.84%

Nu Skin Corporate Events

Nu Skin’s Earnings Call Highlights Growth and Challenges

Nu Skin Enterprises’ recent earnings call conveyed a positive sentiment, underscored by robust growth in emerging markets and the introduction of innovative products like the Prysm iO. Despite facing challenges in North America and foreign currency impacts, the company’s strategic initiatives and financial enhancements suggest a promising trajectory.

Nu Skin Enterprises Reports Steady Q3 Earnings Amid Strategic Expansion

Nu Skin Enterprises Inc., a global leader in the beauty and wellness industry, operates through a dynamic affiliate platform offering personal care, nutrition, and anti-aging products across nearly 50 markets worldwide. The company, which also includes Rhyz Inc., is known for its innovative approach backed by over 40 years of scientific research.

Nu Skin’s Innovative Study on Skin Health: A Market Game-Changer?

Nu Skin Enterprises, in collaboration with ChinaNorm, is conducting a study titled Study on Carotenoid-Based Instrumental Index. The primary objective is to evaluate the effectiveness of a new biophotonic scanner, the Prysm device, in measuring skin carotenoid levels and analyzing their correlation with dietary and lifestyle factors. This study holds significance for understanding how lifestyle choices impact skin health.

Nu Skin Enterprises Surpasses Earnings Expectations Amid Challenges

Nu Skin Enterprises recently held its earnings call, revealing a blend of positive achievements and ongoing challenges. The company surpassed earnings expectations, demonstrating strong growth in Latin America and improvements in operational efficiency. However, it faces hurdles with declining revenues in North America and economic difficulties in China and South Korea. Despite these obstacles, the overall sentiment remains cautiously optimistic, driven by strategic plans and performance metrics.

Nu Skin Enterprises Reports Strong Q2 2025 Results

Nu Skin Enterprises Inc. is an integrated beauty and wellness company that operates globally, offering personal care, nutrition, and anti-aging products through a dynamic affiliate platform.